Since its inception on November 15, 2023, Evergrowth has strategically focused on clinical-stage and early product-stage public biotech equities, driving innovation that brings hope to patients worldwide. Our fund is designed to outperform major market benchmarks, including the Dow Jones Industrial Average (INDU), Nasdaq Biotechnology Index (NBI), and SPDR S&P 500 ETF Trust (SPY), over the long term.

As of October 19, 2024, Evergrowth has delivered an impressive return of over 51.45% since inception. (Please note: these are unaudited results.) We remain committed to delivering superior value for our investors while supporting transformative advancements in the biotech sector.